批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/07/15 |
SUPPL-45(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/01/22 |
SUPPL-42(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2024/01/19 |
SUPPL-40(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/06/11 |
SUPPL-26(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/06/11 |
SUPPL-16(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/06/11 |
SUPPL-14(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2001/02/14 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1995/12/22 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1994/03/16 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
|
|
|
1991/09/24 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:FENTANYL CITRATE 剂型/给药途径:INJECTABLE;INJECTION 规格:EQ 0.05MG BASE/ML 治疗等效代码:AP
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
016619 |
001 |
NDA |
SUBLIMAZE PRESERVATIVE FREE |
FENTANYL CITRATE |
INJECTABLE;INJECTION |
EQ 0.05MG BASE/ML |
Prescription |
Yes |
Yes |
AP |
Approved Prior to Jan 1, 1982
|
RISING |
019101 |
001 |
NDA |
FENTANYL CITRATE |
FENTANYL CITRATE |
INJECTABLE;INJECTION |
EQ 0.05MG BASE/ML |
Prescription |
Yes |
Yes |
AP |
1984/07/11
|
HIKMA |
019115 |
001 |
NDA |
FENTANYL CITRATE |
FENTANYL CITRATE |
INJECTABLE;INJECTION |
EQ 0.05MG BASE/ML |
Prescription |
No |
No |
AP |
1985/01/12
|
HOSPIRA |
072786 |
001 |
ANDA |
FENTANYL CITRATE PRESERVATIVE FREE |
FENTANYL CITRATE |
INJECTABLE;INJECTION |
EQ 0.05MG BASE/ML |
Prescription |
No |
No |
AP |
1991/09/24
|
HOSPIRA |
210762 |
001 |
ANDA |
FENTANYL CITRATE PRESERVATIVE FREE |
FENTANYL CITRATE |
INJECTABLE;INJECTION |
EQ 0.05MG BASE/ML |
Prescription |
No |
No |
AP |
2019/05/03
|
FRESENIUS KABI USA |
212086 |
001 |
ANDA |
FENTANYL CITRATE |
FENTANYL CITRATE |
INJECTABLE;INJECTION |
EQ 0.05MG BASE/ML |
Prescription |
No |
No |
AP |
2020/09/01
|
FRESENIUS KABI USA |